U.S. National Library of Medicine
National Center for Biotechnology Information

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Duvelisib. [Updated 2019 Oct 23].
Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

Duvelisib

Revised: October 23, 2019.

CASRN: 1201438-56-3



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of duvelisib during breastfeeding. Because duvelisib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during duvelisib therapy and for at least 1 month after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Duvelisib

CAS Registry Number

1201438-56-3

Drug Class

Lactation

Breast Feeding

Antineoplastic Agents

Enzyme Inhibitors

Kinase Inhibitors

Phosphatidylinositol 3-kinases